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Abstract
Background—Phenotypes of eosinophilic esophagitis (EoE) are not well characterized.
Objective—To describe clinical features of EoE patients with predefined phenotypes, determine 
predictors of these phenotypes, and make inferences about the natural history of EoE.
Design—Retrospective study.
Setting—Tertiary care center.
Patients—Incident EoE cases from 2001–2011 who met consensus diagnostic guidelines.
Interventions—n/a
Main outcome measurements—Endoscopic phenotypes, including fibrostenotic, 
inflammatory, or mixed. Other groups of clinical characteristics examined included atopy, level of 
esophageal eosinophilia, and age of symptom onset. Multinominal logistic regression assessed 
predictors of phenotype status.
Results—Of 379 cases of EoE identified, there were no significant phenotypic differences by 
atopic status or level of eosinophilia. Those with the inflammatory phenotype were more likely to 
be younger than those with mixed or fibrostenotic (13 vs 29 vs 39 years, respectively; p<0.001), 
and less likely to have dysphagia, food impaction, and esophageal dilation (p<0.001 for all). The 
mean symptom length prior to diagnosis was shorter for inflammatory (5 vs 8 vs 8 years; p=0.02). 
After multivariate analysis, age and dysphagia independently predicted phenotype. The OR for 
fibrostenosis for each 10-year increase in age was 2.1 (1.7–2.7). The OR for dysphagia was 7.0 
(2.6–18.6).
Limitations—Retrospective, single-center study.
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Conclusions—In this large EoE cohort, the likelihood of fibrostenosing disease increased 
markedly with age. For every ten year increase in age, the odds of having a fibrostenotic EoE 
phenotype more than doubled. This association suggests that the natural history of EoE is a 
progression from an inflammatory to a fibrostenotic disease.
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Introduction
Over the past decade, eosinophilic esophagitis (EoE) has rapidly emerged as an important 
cause of upper GI disease.1 EoE is defined as a clinicopathologic immune/allergen-mediated 
disorder characterized by symptoms of esophageal dysfunction and a marked eosinophilic 
infiltrate on esophageal biopsy.2 EoE appears to be a chronic disease, but there are few 
cohorts that have been observed long-term without therapeutic interventions.3, 4 In general, 
patients with EoE tend to be younger, male, white, and have associated atopic disorders.5 
Dysphagia is the hallmark symptom of EoE, and EoE is the cause in more than 50% of cases 
of food impaction presenting to the emergency department.2, 5, 6 Typical findings on 
endoscopy include esophageal rings, linear furrows, white plaques or exudates, decreased 
vascularity, strictures, and mucosal fragility.7, 8
Despite these commonalities, there can be substantial variability in EoE at the patient level. 
It is well recognized that clinical and endoscopic features of children and adults with EoE 
differ.2, 5, 7, 9–13 Children tend to present with heartburn, vomiting, abdominal pain, feeding 
intolerance, or failure to thrive, while adults primarily present with dysphagia. While adults 
often have esophageal rings and strictures requiring dilation, children tend to have more 
furrows, plaques, and decreased vascularity on endoscopy. Similarly, while atopy is 
common in EoE, it is by no means universal.9, 14–17 Recently, there has been a question of 
whether different EoE phenotypes are responsible for divergent clinical presentations and 
outcomes.2, 18, 19 However, it is unknown whether specific phenotypes accurately 
characterize subgroups of patients with EoE and whether these phenotypes are the result of 
disease progression. It is also unknown whether EoE is a disease consisting of one or more 
discrete subtypes, or whether it is a single condition with changes in expression over time. In 
the latter conception, the manifestations primarily present in children and young adults 
might represent an early inflammatory phase, while the manifestations in adults would 
represent chronic fibrostenotic manifestations which are sequelae of this inflammation.
The aim of this study was to describe the clinical features of EoE patients with predefined 
phenotypes, determine predictors of these phenotypes, and make inferences about the natural 
history of EoE. The phenotypes examined include inflammatory, fibrostenotic, and mixed 
phenotypes based on endoscopy, as well as defined clinical characteristics such as atopic 
status, severity of esophageal eosinophilia, and onset of disease.
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Study design, data source, and phenotype definitions
This was a retrospective study conducted at the University of North Carolina (UNC) Center 
for Esophageal Diseases and Swallowing. Using the UNC EoE Clinicopathologic database 
from 2001–2011, subjects with an incident diagnosis of EoE made at UNC who met 
consensus diagnostic guidelines were included. Specifically, all patients had symptoms of 
esophageal dysfunction, ≥15 eos/hpf (hpf area=0.24 mm2), and did not respond to a proton 
pump inhibitor (PPI) trial.2, 20 Details of the development of this database and confirmation 
of EoE case status have previously been described.9, 21, 22 This study was approved by the 
UNC Institutional Review Board.
Data were extracted from electronic medical records, endoscopy reports, and pathology 
records. Specific data included: demographics (age at diagnosis, gender, race); symptoms; 
duration of symptoms prior to EoE diagnosis; co-existing atopic disease (allergic rhinitis or 
sinusitis, asthma, or documented food allergy demonstrated by either symptomatic evidence 
of allergy with reintroduction of a food or by testing directed by an Allergist); and 
endoscopic findings (rings, strictures, esophageal narrowing, linear furrows, white plaques 
or exudates, decreased vascularity, crêpe-paper mucosa, erosive esophagitis, and hiatal 
hernia) and maneuvers (dilation). For histologic assessment, the maximum eosinophil count 
(eos/hpf; hpf area = 0.24 mm2) had been determined for clinical purposes using a standard 
protocol which has been shown to have excellent interobserver correlation for both attending 
and resident pathologists.23, 24
EoE phenotypes were defined a priori as follows. Endoscopic phenotypes reflected the 
degree of inflammation versus remodelling noted on esophageal examination. The 
phenotypes were defined as fibrostenotic if there were esophageal rings, narrowing, or 
strictures and no evidence of linear furrows or white plaques; as inflammatory if there were 
furrows, plaques, or a normal esophagus and no evidence of fibrostenotic changes; and as 
mixed if there were a combination of findings. Furrows were considered an inflammatory 
change based on evidence that biopsies from these areas show a highly eosinophilic 
infiltrate, and that furrowing is rapidly reversible with topical steroids.25–28 We also 
assessed cases of EoE by other baseline disease characteristics. Atopy was defined as 
subjects with allergic rhinitis, sinusitis, dermatitis, asthma, or food allergy. We stratified 
esophageal eosinophilia by tertiles (15–50 eos/hpf, 51–99, eos/hpf and ≥100 eos/hpf). 
Disease onset was separated into childhood disease onset (first symptoms at <18 yrs) versus 
adult disease onset. Because we had data concerning symptom duration prior to diagnosis of 
EoE, we estimated approximate date of disease onset by subtracting the pre-diagnosis 
symptom duration from the date of diagnosis. For instance, an adult diagnosed at age 30 
would be considered to have childhood disease onset if symptoms had been present for more 
than 12 years.
Statistical analysis
Descriptive statistics were used to characterize clinical, endoscopic, and histologic features 
of the EoE population in general, and then to characterize features of each of the EoE 
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phenotypes. Features were then compared between the different phenotype definitions. 
Specifically, the three phenotypes were compared, the atopic/non atopic subjects were 
compared, the eosinophil tertiles were compared, and the age of onset was compared. Means 
were compared with t-tests and proportions were compared by chi-square. Finally, 
multinominal logistic regression was performed to assess predictors of phenotype status 
amongst the three phenotypes. Odds ratios (ORs) were assessed for multiple factors based 
on the initial bivariate analysis including age (10 year increments), gender, race, symptoms 
(dysphagia, heartburn, abdominal pain, vomiting), atopy, food allergies, and eosinophil 
counts. The model was then reduced using a backwards elimination strategy that removed 
factors that were not significant at the p < 0.05 level. We analyzed a separate model that 
included symptom duration, as this was colinear with age.
Results
Characteristics of EoE cases
A total of 379 EoE cases were identified in the database (Table 1). The mean age was 25 
years (ranging from 6 months to 82 years), 73% were male, and 81% were white. The most 
common symptoms were dysphagia (66%), heartburn (39%), and food impaction (28%), 
with a mean duration of symptoms prior to diagnosis of 7 years. More than one-third of 
patients had some form of atopy. On endoscopy, typical findings of EoE were common, with 
40% having esophageal rings and 40% having linear furrows. The average maximum 
eosinophil count was 86 eos/hpf.
Fibrotic, inflammatory, and mixed phenotypes and phenotype predictors
When the 374 patients with endoscopic data were divided into phenotypes, 134 (36%) were 
inflammatory, 163 (43%) were mixed, and 77 (21%) were fibrostenotic (Table 2). Those 
with an inflammatory phenotype were on average much younger than those with mixed or 
fibrostenotic (13 vs 29 vs 39 years, respectively; p <0.001). Dysphagia was less likely in 
inflammatory compared to mixed or fibrostenotic (36% vs 77% vs 92%; p<0.001), as were 
food impaction (15% vs 37% vs 39%; p<0.001) and esophageal dilation (0% vs 24% vs 
47%; p<0.001). Abdominal pain, vomiting, and failure-to-thrive were more common in the 
inflammatory phenotype (p<0.001 for all), as were atopy and food allergies (p<0.05). The 
mean symptom length prior to diagnosis was shorter for inflammatory compared to mixed 
and fibrostenotic (5 vs 8 vs 8 years; p=0.02). The maximum eosinophil counts did not 
significantly vary between the groups (84 vs 80 vs 102; p=0.12). These results were 
unchanged in a supplemental analysis comparing the inflammatory EoE cases to EoE cases 
with any element of fibrostenosis (ie combining the mixed and fibrostenotic groups) 
(Supplemental Table 1).
After multivariate analysis, only age at diagnosis and dysphagia were independent predictors 
of phenotype status. The OR for a 10 year increase in age for a mixed phenotype compared 
to inflammatory was 1.64 (95% CI 1.35–1.99) and for fibrostenotic was 2.14 (1.70–2.70). 
This indicates that for every decade of life, the odds of developing a fibrostenotic phenotype 
more than doubles. The predicted probability of developing a fibrosteontic EoE phenotype 
by age is graphed in Figure 1. The ORs for the presence of dysphagia as a predictor of 
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mixed or fibrostenosing phenotype were 3.07 (1.71–5.49) and 7.00 (2.63–18.64), 
respectively. When symptom duration prior to EoE was assessed separately, the findings 
were similar. The OR for each 1 year of symptoms prior to EoE diagnosis for a fibrostenotic 
vs inflammatory phenotype was 1.05 (1.01–1.10), indicating that the odds of developing 
fibrostenosis increased 5% with every year of symptoms prior to diagnosis. The OR for a 10 
year symptom duration prior to EoE diagnosis was 1.60 (1.05–2.44).
Atopy, eosinophil counts and age of disease onset
There were 177 EoE cases with atopy, 128 in the highest tertile of eosinophil counts (≥100 
eos/hpf), and 172 with childhood onset of disease. Those with atopy tended to be diagnosed 
at an earlier age than those without atopy (22 vs 26 yrs; p=0.06), but there were no other 
differences by atopic status for gender, race, symptoms, endoscopy findings, or eosinophil 
counts (Supplemental Table 2).
For the eosinophilia phenotype, there were no significant differences by age, gender, race, 
symptoms, atopic status, or endoscopy findings based on eosinophil counts at diagnosis 
(Supplemental Table 3).
Those with childhood onset of EoE were more commonly male (81% vs 67%; p<0.001) and 
non-white (25% vs 15%; p=0.02), had more abdominal pain, vomiting, and failure-to-thrive 
(p<0.01 for all), and less dysphagia (p<0.001) than those with adult onset. While those with 
childhood onset were more likely to have a normal endoscopic exam (28% vs 8%; p<0.001), 
there was no difference in eosinophil count by age of symptom onset (Table 3). These 
results were unchanged in a supplemental analysis where childhood onset was defined as 
age < 12 years (see Supplemental Table 4).
Discussion
With increasing knowledge about EoE, the variability in the disease has been recognized,2 
and differences in characteristics between adults and children7, 9–12 and by race or gender 
have been described.29–31 This has raised the question of whether underlying EoE 
phenotypes are responsible for different clinical presentations and outcomes, and whether 
such phenotypes might impact on or be the result of the natural history of the condition. The 
purpose of this study was to characterize clinical features of predefined EoE phenotypes, 
determine predictors of these phenotypes, and make inferences about the natural history of 
EoE.
We found that fibrostenotic, inflammatory, and mixed phenotypes were associated with 
significant clinical differences between groups of EoE patients. In particular, those with an 
inflammatory phenotype were younger, less likely to have dysphagia, food impaction, or 
esophageal dilation, and more likely to have abdominal pain, vomiting, failure-to-thrive, and 
atopy. Importantly, the mean symptom length prior to diagnosis was shorter for 
inflammatory compared to the mixed and fibrostenotic phenotypes. This suggests that EoE 
may progress from an inflammatory to fibrostenotic disease, and the multivariate analysis 
demonstrates this change in risk over time. For every 10 year increase in age, the odds of 
having a fibrostenotic phenotype more than doubles. The odds were similar for longer 
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duration of symptoms prior to diagnosis. In contrast, baseline atopic status or eosinophil 
count were not associated with important differences in clinical characteristics. High 
eosinophil counts were also seen in EoE patients with a fibrostenotic phenotype and a long 
symptom duration prior to diagnosis, suggesting that the inflammation in this group is not 
“burning out,” or becoming less severe over time.
Our findings support a trend of new thinking about EoE. In recent years there has been much 
discussion about possible phenotypes of EoE, though there are few published data on this 
topic.2, 18, 32, 33 It has been well described that symptoms differ between adults and children 
and appear to progress, with failure to thrive and feeding intolerance in the youngest 
children, then abdominal pain, vomiting/regurgitation, and heartburn in older children, then 
dysphagia and food impaction in adolescents and adults.9–12 Similarly, endoscopic findings 
have been reported to vary by age as well, with a normal appearing esophagus, linear 
furrows, and white plaques more common in children, and esophageal rings, strictures, and 
narrowing more common in adults.7, 9, 13 In natural history studies, while there are few 
children who have been observed for many years without treatment,3, 14, 15, 34, 35 
progression from inflammatory to fibrostenotic phenotypes has been noted anecdotally.
In our study, there was highly active eosinophilic inflammation in all patients, regardless of 
phenotype. One could postulate that with longer exposure to inflammation, there is a higher 
risk of fibrosis. Indeed, eosinophilic inflammation resulting in esophageal fibrosis has been 
well described in studies of the pathogenesis of EoE. Aceves and colleagues first reported 
sub-epithelial fibrosis in children with EoE,36 and this has been confirmed in both children 
and adults.37–39 Fibrosis appears to be mediated by active eosinophilic and mastocytotic 
inflammation in the esophageal mucosa,36, 40–42 and may involve deeper layers of the 
esophagus wall, as suggested by endoscopic ultrasound imaging.43–45 Kwiatek, Hirano, and 
colleagues have used a novel functional lumen imaging probe to characterize decreased 
esophageal compliance in patients with EoE, a result of ongoing esophageal remodelling and 
fibrosis.46 They have also shown that esophageal compliance correlates with 
endoscopically-defined phenotypes of EoE,26, 47 similar to the phenotypes used in this 
study. Our findings are also consistent with recent data presented by Schoepfer, Straumann, 
and colleagues showing that the duration of untreated inflammation is strongly associated 
with stricture development.48 Specially, they found that 17% of subjects with 0–2 years of 
symptom duration had a stricture, compared to 38% with 9–11 years and 67% with more 
than 20 years. Taken in the context of these data, our results support the hypothesis that 
fibrostenotic complications are likely the result of chronic inflammation leading to disease 
progression in EoE.
In addition to improving our understanding of the pathogenesis of EoE, recognition of 
phenotypes of EoE may also have implications for treatment decisions and outcome 
assessment. For example, if EoE is progressive, there may be an impetus to aggressively 
treat eosinophilic inflammation in subjects who have not yet developed fibrostenotic 
complications in order to prevent esophageal stricture development. Data suggest that 
children who are treated may not have the severe phenotypes that are seen in adults who are 
diagnosed after prolonged symptoms,34, 49, 50 and that long-term topical corticosteroid 
treatment might alter the natural history of EoE.51 EoE phenotype might also dictate specific 
Dellon et al. Page 6













treatments. Patients with fibrostenosis might require dilation as a primary treatment, 
particularly since symptoms and levels of esophageal inflammation correlate poorly or not at 
all.19, 33, 52, 53 Additionally, for drug development, patients with a predominantly 
inflammatory phenotype, as opposed to those with established fibrostenosis, may be a 
desirable target population for new medications with a strong anti-eosinophil/anti-
inflammatory effect.
In interpreting the results from this study, there are potential limitations. First, this is a 
retrospective study from a single center, so the generalizability of the results is unclear. 
However, the characteristics of this EoE population are quite similar to EoE patients 
reported from other centers and practice settings. Because it relies on endoscopically-
defined phenotypes, the reproducibility of these findings may be questioned (for example, 
the definition of “narrowing” is not standardized). However, recent work suggests there is 
fair to good agreement among gastroenterologists for endoscopic findings of EoE.8, 54 
Additionally, the data presented here are cross-sectional in nature, but are being used to 
make inferences about disease progression. While the ideal study design to accomplish this 
would be a long-term prospective cohort study, it is neither practical nor ethical to observe a 
population of EoE cases for a decade or more to determine the true rate of fibrostenotic 
complications. Furthermore, increasing risk for fibrostenotic progression was found to be 
not only associated with age (a cross-sectional measure), but also with symptom duration 
prior to diagnosis, a factor that capitulates retrospectively what a prospective cohort study 
would measure. However, we acknowledge that confounding factors (for example, 
concomitant use by atopic patients of intranasal or inhaled corticosteroids) could impact the 
course of the disease, and therefore the observed EoE phenotype. Finally, this paper is 
limited to clinicopathologic phenotypes. Future studies might determine whether 
genetically-defined phenotypes of EoE exist and might be used for diagnosis, prognosis, or 
to guide therapy.
The strengths of this study should also be acknowledged. This is large sample of well-
characterized EoE cases that provides sufficient power to subdivide the population in 
multiple phenotypes. We selected phenotypes a priori that match the evolving 
understanding of EoE. In addition, the predictive analysis using multinomial regression can 
provide patients with quantifiable data as to what to expect for disease progression.
In conclusion, in this large cohort of subjects with EoE, the likelihood of fibrostenosing 
disease increased with age. For every ten year increase in age, the odds of having a 
fibrostenotic EoE phenotype more than doubled. The association of fibrostenosis with age 
suggests that the natural history of EoE is a progression from an inflammatory to a 
fibrostenotic disease. Further work should confirm these findings, and assess whether these 
phenotypes predict response to various therapies or prognosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Characteristics of patients with EoE (n = 379)
Characteristic N (%) or mean ± SD
Age at diagnosis (mean years ± SD, range) 25.3 ± 18.7 (0.6–82)
 Adults ≥ 18 years 199 (53)
Males (n, %) 278 (73)
Whites (n, %) 305 (81)
Symptoms (n, %)
 Dysphagia 244 (66)
 Food impaction 100 (28)
 Heartburn 139 (39)
 Chest pain 33 (9)
 Abdominal pain 83 (23)
 Nausea 38 (11)
 Vomiting 91 (26)
 Failure to thrive 49 (14)
Symptom length prior to diagnosis (mean years ± SD) 7.1 ± 8.8
Atopic diseases (n, %)*
 Allergic rhinitis/sinusitis/dermatitis 125 (38)
 Asthma 89 (27)
 Food allergy 62 (19)
Endoscopic findings (n, %)†
 Normal 63 (17)
 Rings 148 (40)
 Stricture 66 (18)
 Narrowing 44 (12)
 Linear furrows 150 (40)
 White plaques 81 (22)
 Decreased vascularity 58 (16)
 Crêpe-paper mucosa 23 (6)
 Erosive esophagitis 89 (24)
 Hiatal hernia 35 (9)
 Dilation performed 76 (20)
Maximum eosinophil count (mean eos/hpf ± SD; range) 85.7 ± 81.1 (15–609)
*
Data were available on atopic status for 332 subjects
†
Data were available on EGD findings for 374 subjects
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Table 2
Comparison of inflammatory, mixed, and fibrostenotic phenotypes of EoE
Inflammatory (n = 134; 
36%)
Mixed (n = 163; 43%) Fibrostenotic (n = 77; 
21%)
p*
Age (mean years ± SD) 13.3 ± 14.4 29.1 ± 16.9 39.2 ± 16.3 < 0.001
 Adults ≥ 18 years 26 (19) 111 (68) 62 (81) < 0.001
Males (n, %) 99 (74) 120 (74) 54 (70) 0.82
Whites (n, %) 92 (69) 142 (88) 68 (88) < 0.001
Symptoms (n, %)
 Dysphagia 47 (36) 123 (77) 70 (92) < 0.001
 Food impaction 15 (12) 56 (37) 27 (39) <0.001
 Heartburn 63 (49) 57 (37) 18 (27) 0.008
 Chest pain 8 (6) 18 (12) 7 (10) 0.25
 Abdominal pain 51 (39) 24 (16) 8 (12) < 0.001
 Nausea 20 (15) 6 (4) 10 (15) 0.003
 Vomiting 54 (41) 22 (15) 11 (16) < 0.001
 Failure to thrive 33 (26) 13 (9) 1 (1) < 0.001
Symptom length prior to dx (mean years ± 
SD)
5.3 ± 7.6 8.3 ± 9.4 8.4 ± 9.2 0.02
Atopic diseases (n, %)
 Allergic rhinitis, sinusitis, dermatitis 50 (39) 59 (39) 13 (20) 0.01
 Asthma 35 (27) 41 (27) 13 (20) 0.47
 Food allergy 32 (27) 20 (15) 9 (18) 0.05
Endoscopic findings (n, %)
 Normal 63 (47) 0 0 -
 Rings 0 87 (53) 61 (79) -
 Stricture 0 31 (19) 35 (45) -
 Narrowing 0 31 (19) 13 (17) -
 Linear furrows 56 (42) 94 (58) 0 -
 White plaques 39 (29) 42 (26) 0 -
 Decreased vascularity 25 (19) 24 (15) 9 (12) 0.38
 Crêpe-paper 7 (5) 12 (7) 4 (5) 0.69
 Erosive esophagitis 14 (10) 48 (29) 27 (35) < 0.001
 Hiatal hernia 2 (1) 23 (14) 10 (13) < 0.001
 Dilation performed 0 39 (24) 37 (47) -
Max eosinophil count (mean eos/hpf ± SD) 84.2 ± 75.9 79.3 ± 78.4 102.3 ± 95.4 0.12
*
p values calculated using a one-way ANOVA for continuous variables and chi-square for categorical variables; p values were not compared for 
the endoscopic findings used to construct the phenotype groups.
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Table 3
Comparison of EoE characteristics by pediatric versus adult onset of disease
Peds. onset (n = 172; 45%) Adult onset (n = 207; 55%) p*
Age (mean years ± SD) 12.7 ± 11.3 35.7 ± 17.1 --
 Adults ≥ 18 years -- -- --
Males (n, %) 140 (81) 138 (67) 0.001
Whites (n, %) 129 (75) 176 (85) 0.02
Symptoms (n, %)
 Dysphagia 75 (44) 169 (83) < 0.001
 Food impaction 35 (21) 65 (35) 0.003
 Heartburn 73 (43) 66 (35) 0.12
 Chest pain 8 (5) 25 (13) 0.005
 Abdominal pain 51 (30) 32 (17) 0.004
 Nausea 17 (10) 21 (11) 0.72
 Vomiting 62 (37) 29 (16) < 0.001
 Failure to thrive 40 (24) 9 (5) < 0.001
Symptom length prior to dx (mean years ± SD) 6.4 ± 8.2 8.2 ± 9.7 0.10
Atopic diseases (n, %)
 Allergic rhinitis, sinusitis, dermatitis 36 (39) 61 (33) 0.28
 Asthma 51 (31) 38 (20) 0.03
 Food allergy 36 (24) 26 (17) 0.11
Endoscopic findings (n, %)
 Normal 47 (28) 16 (8) < 0.001
 Rings 33 (19) 115 (56) < 0.001
 Stricture 14 (8) 52 (25) < 0.001
 Narrowing 13 (8) 31 (15) 0.02
 Linear furrows 60 (35) 90 (44) 0.08
 White plaques 42 (25) 39 (19) 0.19
 Decreased vascularity 38 (22) 20 (10) 0.001
 Crêpe-paper 16 (9) 7 (3) 0.02
 Erosive esophagitis 42 (25) 47 (23) 0.71
 Hiatal hernia 6 (4) 29 (14) < 0.001
 Dilation performed 13 (8) 63 (31) < 0.001
Max eosinophil count (mean eos/hpf ± SD) 81.8 ± 69.7 88.9 ± 89.4 0.40
*
p values calculated using a t-test for continuous variables and chi-square for categorical variables.
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